Liaoning Chengda Biotechnology Co. Ltd. Class ASSE: 688739

"LIAONING CHENGDA BIOTECHNOLOGY CO., LTD."Announcement on the Influenza Virus Split Vaccine Obtaining Drug Registration Certificate and Passing GMP Compliance Inspection

Jul 3, 2026 · Issued by Liaoning Chengda Biotechnology Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on the Influenza Virus Split Vaccine Obtaining Drug Registration Certificate and Passing GMP Compliance Inspection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Liaoning Chengda Biotechnology Co. Ltd. Class A

Announcement on Obtaining Drug Registration Certificate for Quadrivalent Influenza Vaccine (Split Virion) and Passing GMP Compliance Inspection for DrugsJun 17
Announcement on Implementation Result of Shares Repurchase and Share ChangesJun 12
Announcement on Progress in Joint Investment with the Controlling Shareholder and Its Wholly-owned Subsidiary and Related Party TransactionsJun 6
Announcement on Progress in Repurchasing Shares through Call AuctionJun 3

All Liaoning Chengda Biotechnology Co. Ltd. Class A news releases